A Phase 1 Single Center, Randomized, Double-Blind, Ascending, Multi-Dose, Within-Subject Controlled Study of RXI-109 for the Treatment of Incision Scars Made in the Abdominal Skin of Healthy Subjects
Latest Information Update: 14 Jan 2020
At a glance
- Drugs PH 109 (Primary)
- Indications Scars
- Focus Adverse reactions
- Sponsors Phio Pharmaceuticals; RXi Pharmaceuticals
- 02 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Jan 2014 New trial record